mTOR Inhibition for Cancer Therapy: Past, Present and Future
120,00 €*
Sofort verfügbar, Lieferzeit: 1-3 Tage
Produktnummer:
9782817804910
This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.
EAN: | 9782817804910 |
---|---|
Auflage: | 001 |
Sprache: | Englisch |
Seitenzahl: | 308 |
Produktart: | Gebunden |
Herausgeber: | Mita, Monica Rowinsky, Eric K. Mita, Alain |
Verlag: | Springer France S.A.R.L. Springer Paris |
Veröffentlichungsdatum: | 01.12.2015 |
Schlagworte: | Forschung (medizinisch, psychologisch) Hämatologie Krebs (Krankheit) Tumor / Krebs Heilkunde Humanmedizin Medizin Biologie / Molekularbiologie Molekularbiologie Krebs (Krankheit) / Onkologie Onkologie - Radioonkologie Arznei / Arzneimittellehre Pharmakologie |
Größe: | 22 × 160 × 241 |
Gewicht: | 685 g |